Abstract
Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have